degarelix 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
gonadotropin-releasing-hormone (GnRH) inhibitors, peptides 4379 214766-78-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • degarelix
  • firmagon
  • degarelix acetate
FE-200486 is the acetate salt
  • Molecular weight: 1632.29
  • Formula: C82H103ClN18O16
  • CLOGP: -0.74
  • LIPINSKI: 3
  • HAC: 34
  • HDO: 17
  • TPSA: 512.87
  • ALOGS: -5.60
  • ROTB: 41

Drug dosage:

DoseUnitRoute
2.70 mg P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.74 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.68 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 18.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 24, 2008 FDA FERRING
June 26, 2012 PMDA Astellas Pharma Inc.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site erythema 291.20 19.93 107 5570 13849 29555001
Injection site pain 291.09 19.93 136 5541 32310 29536540
Prostatic specific antigen increased 203.08 19.93 80 5597 12484 29556366
Injection site swelling 199.24 19.93 73 5604 9344 29559506
Injection site induration 145.21 19.93 42 5635 2534 29566316
Hot flush 132.02 19.93 62 5615 14808 29554042
Osteonecrosis of jaw 122.87 19.93 61 5616 16449 29552401
Injection site nodule 82.97 19.93 24 5653 1446 29567404
Injection site mass 82.00 19.93 33 5644 5422 29563428
Injection site reaction 76.34 19.93 39 5638 11149 29557701
Injection site cellulitis 60.77 19.93 15 5662 489 29568361
Metastases to bone 57.53 19.93 31 5646 9867 29558983
Injection site warmth 57.04 19.93 19 5658 1827 29567023
Interstitial lung disease 49.29 19.93 58 5619 57660 29511190
Hypocalcaemia 45.26 19.93 35 5642 20630 29548220
Prostate cancer metastatic 44.93 19.93 21 5656 4945 29563905
Prostatic specific antigen abnormal 42.91 19.93 11 5666 419 29568431
Injection site abscess 41.90 19.93 12 5665 697 29568153
Necrotising retinitis 40.95 19.93 12 5665 756 29568094
Injection site inflammation 33.45 19.93 10 5667 675 29568175
Blood testosterone abnormal 31.22 19.93 8 5669 304 29568546
Prescribed underdose 30.83 19.93 19 5658 7767 29561083
Injection site discomfort 30.77 19.93 11 5666 1306 29567544
Malignant neoplasm progression 28.59 19.93 51 5626 73808 29495042
Infusion site plaque 27.46 19.93 4 5673 4 29568846
Blood testosterone increased 25.94 19.93 9 5668 979 29567871
Prostate cancer 24.02 19.93 27 5650 25500 29543350
Toxic cataract 23.07 19.93 4 5673 20 29568830
Prostatic specific antigen decreased 22.64 19.93 5 5672 99 29568751
Metastases to spine 22.18 19.93 10 5667 2166 29566684
Malaise 22.06 19.93 74 5603 159528 29409322
Product lot number issue 21.68 19.93 4 5673 30 29568820
Mucocutaneous disorder 21.64 19.93 5 5672 122 29568728
Hormone-refractory prostate cancer 21.55 19.93 7 5670 622 29568228
Retinal detachment 20 19.93 12 5665 4674 29564176
Bone pain 19.95 19.93 21 5656 18431 29550419

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prostatic specific antigen increased 228.68 22.86 63 4539 8697 64485433
Injection site pain 159.54 22.86 99 4503 111309 64382821
Injection site erythema 152.23 22.86 82 4520 70718 64423412
Osteonecrosis of jaw 123.14 22.86 59 4543 39766 64454364
Injection site swelling 109.14 22.86 55 4547 41298 64452832
Injection site induration 101.97 22.86 34 4568 8898 64485232
Hot flush 81.37 22.86 47 4555 46188 64447942
Injection site mass 60.77 22.86 28 4574 17242 64476888
Injection site nodule 60.71 22.86 18 4584 3212 64490918
Interstitial lung disease 57.66 22.86 51 4551 97681 64396449
Prostate cancer metastatic 51.75 22.86 16 4586 3288 64490842
Hypocalcaemia 49.44 22.86 33 4569 41720 64452410
Injection site cellulitis 49.34 22.86 13 4589 1508 64492622
Necrotising retinitis 48.86 22.86 12 4590 1051 64493079
Injection site abscess 45.60 22.86 12 4590 1386 64492744
Prostate cancer 42.64 22.86 23 4579 19772 64474358
Metastases to bone 39.21 22.86 22 4580 20413 64473717
Infusion site plaque 31.42 22.86 4 4598 4 64494126
Prostatic specific antigen decreased 29.70 22.86 5 4597 63 64494067
Prescribed underdose 28.21 22.86 17 4585 17998 64476132
Toxic cataract 27.03 22.86 4 4598 20 64494110
Blood testosterone increased 26.85 22.86 7 4595 779 64493351
Hormone-refractory prostate cancer 26.56 22.86 6 4596 366 64493764
Mucocutaneous disorder 26.16 22.86 5 4597 133 64493997
Urinary retention 25.69 22.86 24 4578 49177 64444953
Retinal detachment 25.17 22.86 12 4590 7964 64486166
Injection site reaction 24.82 22.86 23 4579 46641 64447489
Injection site inflammation 24.25 22.86 9 4593 3212 64490918
Prostatic specific antigen abnormal 23.88 22.86 5 4597 213 64493917
Decreased appetite 23.78 22.86 58 4544 281231 64212899
Metastases to spine 23.17 22.86 9 4593 3634 64490496

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BX02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Other hormone antagonists and related agents
FDA PE N0000008638 Decreased GnRH Secretion
FDA MoA N0000175084 Gonadotropin Releasing Hormone Receptor Antagonists
FDA EPC N0000175839 Gonadotropin Releasing Hormone Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Advanced Prostatic Carcinoma indication
Torsades de pointes contraindication 31722008
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Osteopenia contraindication 312894000
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.99 acidic
pKa2 11.49 acidic
pKa3 12.21 acidic
pKa4 12.25 acidic
pKa5 12.82 acidic
pKa6 13.11 acidic
pKa7 13.11 acidic
pKa8 13.39 acidic
pKa9 13.47 acidic
pKa10 13.85 acidic
pKa11 9.64 Basic
pKa12 5.35 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10729739 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10973870 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9579359 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10729739 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10973870 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9579359 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10695398 April 27, 2032 METHOD OF TREATING PROSTATE CANCER
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9415085 April 27, 2032 METHOD OF TREATING PROSTATE CANCER
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10695398 April 27, 2032 METHOD OF TREATING PROSTATE CANCER
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9415085 April 27, 2032 METHOD OF TREATING PROSTATE CANCER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Gonadotropin-releasing hormone receptor GPCR ANTAGONIST Ki 8.77 IUPHAR CHEMBL

External reference:

IDSource
D08635 KEGG_DRUG
4028567 VUID
N0000178334 NUI
934246-14-7 SECONDARY_CAS_RN
4028567 VANDF
C1455035 UMLSCUI
CHEBI:135961 CHEBI
CHEMBL415606 ChEMBL_ID
CHEMBL2028987 ChEMBL_ID
DB06699 DRUGBANK_ID
C431566 MESH_SUPPLEMENTAL_RECORD_UI
5585 IUPHAR_LIGAND_ID
8192 INN_ID
SX0XJI3A11 UNII
16136245 PUBCHEM_CID
475230 RXNORM
164686 MMSL
168716 MMSL
26319 MMSL
d07411 MMSL
012979 NDDF
012980 NDDF
441758000 SNOMEDCT_US
441864003 SNOMEDCT_US

Pharmaceutical products:

None